FDA approves Sunosi (solriamfetol) to treat over-day drowsiness associated with OSA syndrome

today,the FDA(http://announced the approval of Jazz Pharmaceuticals's(http://to treat daytime excessive drowsiness associated with narcolepsy or obstructive sleep apnea (OSA) syndromeAbout Solriamfetol
Solriamfetol is a selective dopamine and norepinephrine reuptake inhibitor (DNRI)It can lead to higher levels of dopamine and norepinephrine, which can directly stimulate the wake-up neurons in the brain, while norepinephrine may shut down the sleep driver by acting on the peripheral pre-optic nucleus (VLPO) of the hypothalamusAs a result, thisnew drug(http://may be a dual mechanism to promote patients to stay awakeother current treatments for drowsinessdrug(http://mostly work by stimulating the release of dopamine, which can lead to a surge in dopamine levels and give patients a sense of euphoria, which is at risk of addictionSolriamfetol does not stimulate the release of dopamine, thereby reducing the risk of addictionSolriamfetol's approval is based on a TONES research project that includes a number of Phase 3 clinicaltrials(http://, including to
nES 2 clinical trials for patients with onset sleeping and to
nES 3 and To
nES 4 clinical trials for patients with OSA, as well as to
nES 5 clinical trials to assess long-term safetySolriamfetol not only significantly improved the patient's wakefulness and drowsiness scores in clinical trials, but also demonstrated good safety and tolerance